IBRX Q1 2019 Earnings — ImmunityBio, Inc. Revenue & Financial Results | Market Cap Arena

IBRXImmunityBio, Inc.

$8B

Q1 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$5,000+0.0% YoY

Gross Profit

$5,000100.0% margin

Operating Income

-$18M-358360.0% margin

Net Income

-$18M-357700.0% margin

EPS (Diluted)

$-0.06

QoQ Revenue Growth

-28.6%

Cash Flow

Operating Cash Flow

-$13M

Free Cash Flow

-$15M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$208M

Total Liabilities

$40M

Stockholders' Equity

$168M

Cash & Equivalents

$22M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$5,000	$5,000	+0.0%
Gross Profit	$5,000	$5,000	+0.0%
Operating Income	-$18M	-$28M	+35.1%
Net Income	-$18M	-$28M	+35.0%